Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains ...

HealthCare.gov open enrollment runs Nov. 1, 2026, to Jan. 15, 2027, and the 2027 out-of-pocket ceiling rises to $12,000. Here ...

A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take ...

After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on ...

For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: ...

From a new chemotherapy combination to the first RAS-targeted pill, here's what five years of pancreatic cancer approvals mean for patients.

After a blood cancer diagnosis, a survivor reflects on the close friends who let her be herself and asks whether she is the ...

Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, ...

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

A Phoenix man with metastatic castration-sensitive prostate cancer shares how back pain led to a PSA test and how his family helped him cope. Prostate cancer grows slowly, and while 50% of men on ...

For people with lung or pancreatic cancer driven by changes in the KRAS gene, research presented at the 2026 European Society ...

Four phase 3 trials at ESMO 2026 brought news for people with small cell, EGFR, MET and KRAS G12C lung cancer, plus a caution ...